Key terms
About GOSS
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GOSS news
May 09
12:45pm ET
Buy Rating Affirmed for Gossamer Bio Amidst Strategic Collaboration and Market Opportunity Growth
May 08
11:11am ET
Biotech Alert: Searches spiking for these stocks today
May 07
11:55pm ET
Strategic Partnership and Financial Upside: Gossamer Bio Earns a Buy Rating
May 07
4:15pm ET
Gossamer Bio reports Q1 EPS (19c), consensus (19c)
May 07
8:55am ET
Wedbush Sticks to Its Buy Rating for Gossamer Bio (GOSS)
May 06
8:21pm ET
Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS), RxSight (RXST) and Edwards Lifesciences (EW)
May 06
2:25pm ET
Buy Rating on Gossamer Bio Supported by Strategic Partnership and Market Underestimation
May 06
2:19pm ET
Goldman says Gossamer’s new deal validates attractive opportunity for seraltunib
May 06
12:23pm ET
Gossamer Bio partnership with Chiesi a positive, says Guggenheim
May 06
12:10pm ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: GlycoMimetics (GLYC) and Gossamer Bio (GOSS)
May 06
11:58am ET
Gossamer collaboration should accelerate development, says H.C. Wainwright
May 06
10:56am ET
Gossamer Bio seralutinib partnership a clear win, says Cantor Fitzgerald
May 06
10:44am ET
Piper sees Gossamer Bio partnership as major win for seralutinib in PAH, PH-ILD
May 06
7:43am ET
Gossamer Bio Forms Major Alliance with Chiesi Farmaceutici
May 06
7:38am ET
Gossamer Bio, Chiesi enter seralutinib collaboration
Apr 04
4:21pm ET
Gossamer Bio assumed with an Outperform at Wedbush
Apr 04
12:10pm ET
Piper Sandler pharmaceuticals analysts hold an analyst/industry conference call
Mar 21
9:00am ET
Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Gossamer Bio (GOSS) and Vor Biopharma (VOR)
Mar 13
6:55am ET
Piper Sandler Sticks to Its Buy Rating for Gossamer Bio (GOSS)
Mar 12
4:13pm ET
Gossamer Bio Welcomes New Board Members, Enhances Leadership
Mar 11
2:45am ET
Barclays Keeps Their Hold Rating on Gossamer Bio (GOSS)
Mar 06
11:19pm ET
Optimistic Buy Rating for Gossamer Bio Amidst Progress in PAH Treatment Market
Mar 06
7:55am ET
Strong Buy Rating on Gossamer Bio Amidst Seralutinib’s Promising Trials and Solid Financials
Mar 05
8:15pm ET
Gossamer Bio Earns ‘Buy’ Rating from Analyst Citing Progress in Seralutinib Trials and Strategic Market Expansion
Mar 05
6:15pm ET
Maintained Buy Rating on Gossamer Bio Amidst Anticipated Phase 3 PROSERA Trial Results
Mar 05
7:40am ET
Gossamer Bio reports Q4 EPS (21c), consensus (21c)
No recent press releases are available for GOSS
GOSS Financials
Key terms
Ad Feedback
GOSS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GOSS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
